CD44 and ovarian carcinoma: The results suggested that the proliferation inhibition and apoptosis rate of ovarian cancer HO8910 cells treated with DDP/CD44-shRNA/MFH was 91.33 ± 0.22%, while that of the DDP/MFH group was 84.32 ± 1.02%, indicating that the inhibition is mainly due to the chemotherapeutic drug and MFH with little effect of combined CD44-shRNA.